Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Organon’s contraceptive completes European authorization
NuvaRing is already approved in 14 European Union territories using the MRP with the Netherlands as the reference member state. National marketing authorizations for the latest countries –
NuvaRing is already approved in 14 European Union territories using the MRP with the Netherlands as the reference member state. National marketing authorizations for the latest countries –
NimbleGen will be integrated into the Roche’s diagnostics division, and the company’s 140 employees will be retained, Roche said. NimbleGen will be further expanding its product portfolio in
The open-label, single-treatment trial in patients with recurrent breast cancer following partial or complete mastectomy used intratumoral administration of bleomycin followed by electroporation, to enhance uptake of the
Results from the company’s investigational study suggested that Orencia reduced flare-ups of the disease in children who were not helped by other anti-rheumatic drugs such as methotrexate or
The FDA issued its third approvable letter, stating that Encysive’s development program for Thelin did not demonstrate the evidence of effectiveness needed for approval. The FDA did note,
The FDA based its decision on results from a randomized, open-label, two-way crossover study of 16 healthy male subjects who received an intravenous infusion of Apidra or regular
Perlegen will use these samples to identify genetic variations that may contribute to a patient’s risk of experiencing adverse events. Results of these analyses may help to direct
The funding from the university will be available on September 1, 2007. Accordingly, ABI will immediately commence preparation of the investigational new drug (IND) application to the FDA.
According to data presented at the Annual European Congress of Rheumatology, Remicade (infliximab)-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance
GlycoPEGylated Factor VIIa is being developed by Novo Nordisk under a license agreement with Neose. The initiation of the phase I study triggers an undisclosed milestone payment to